Three doors, one decision: CAR-T, transplant, or more chemo
When standard chemotherapy stops working, patients with blood cancers face a crossroads. Diffuse large B-cell lymphoma, acute lymphoblastic leukemia, multiple myeloma — these diseases don't stop just because the first treatment round failed. And the options from here are very different.
The three main paths are CAR-T cell therapy, stem cell (bone marrow) transplant, and further chemotherapy. They're often talked about as if they compete — but the truth is more nuanced: they work differently, fit different patients, and sometimes work best together.
This guide compares the three honestly, with the numbers behind them, and explains why China is where many international patients now land for CAR-T — and how the choice is really made.

What each treatment actually does
Chemotherapy kills rapidly dividing cells — including cancer cells, but also healthy ones. It's the backbone of cancer treatment, given in cycles, and it's what patients usually try first. When the cancer returns or stops responding, the chemo is called "salvage" chemotherapy.
Stem cell transplant (bone marrow transplant) replaces your entire blood-producing system. After high-dose chemotherapy empties the bone marrow, healthy stem cells — your own (autologous) or a donor's (allogeneic) — are infused to rebuild it. The donor cells can themselves attack cancer, an effect called graft-versus-leukemia.
CAR-T therapy is different from both. It's not chemotherapy, and it's not a transplant. Your own T cells are collected, genetically engineered in a lab to recognize a specific marker on your cancer cells (like CD19 or BCMA), and infused back to hunt the cancer directly. It's a single infusion of "living drugs."
The key distinction: chemo is a drug, transplant replaces the blood system, and CAR-T engineers your own immune cells.
The numbers: how the treatments compare
The clinical data paints a clear picture of where each treatment shines.
| Disease & setting | Standard chemo | CAR-T | Trial |
|---|---|---|---|
| DLBCL lymphoma (relapsed, 2nd line) | ~20% complete response | ~58% complete response | SCHOLAR-1 vs ZUMA-7 |
| Pediatric B-ALL (refractory) | <10% complete response | ~81% complete response | ELIANA |
| Multiple myeloma (relapsed/refractory) | Limited response | ~73% overall response | CARTITUDE-1 |
The pattern is consistent: in relapsed blood cancers, CAR-T dramatically outperforms further chemotherapy in response rates. That's why CAR-T has become the standard of care for many relapsed or refractory blood cancers in the US and now in China.
The transplant comparison is more nuanced. The best evidence actually shows the two work best together:
- Among patients with high disease burden before infusion, CAR-T followed by consolidative allogeneic transplant significantly improved 2-year overall survival — 68.1% vs 28.3% for CAR-T alone (2-year leukemia-free survival 60.4% vs 27.8%).
- For patients who achieved MRD-negative remission after CAR-T, transplant consolidation improved 2-year OS from 37.8% to 87.9%.
In other words: CAR-T can reduce the disease, and transplant can consolidate the remission. For many patients, the question isn't "CAR-T or transplant" — it's "CAR-T first, transplant to follow."

Who fits which path
Choose CAR-T if:
- You have a relapsed or refractory B-cell cancer (DLBCL, B-ALL, multiple myeloma) after two or more prior lines
- You don't have a suitable donor for transplant
- You want a shorter treatment path (weeks) rather than months of transplant recovery
- Your cancer expresses the right target (CD19, BCMA, or for gastric cancer, CLDN18.2)
Choose transplant if:
- You're in remission and need consolidation to prevent relapse
- You have a suitable donor (allogeneic) or can use your own cells (autologous)
- You have a high genetic risk (e.g., TP53 mutations) where transplant consolidation is proven to help
- CAR-T has already put you into remission — transplant can then lock it in
Choose further chemo if:
- CAR-T and transplant are both unsuitable or unavailable
- You need bridging therapy to control fast-progressing disease before CAR-T or transplant
- The cancer is a type not covered by an approved CAR-T product
The honest answer: for most relapsed blood cancers, chemo alone is the weakest option, and the real decision is usually between CAR-T, transplant, or the powerful combination of CAR-T then transplant.
In myeloma the question has shifted from which path to which order: a BCMA bispecific and BCMA CAR-T can both be used at first relapse, and whichever goes first changes what remains later — we work through that decision for myeloma.
Why patients are going to China for CAR-T
Here's where the decision meets reality — and why China has become a destination for international CAR-T patients.
The price gap is enormous. A CAR-T product lists at ¥0.899M–¥1.299M (about $135,000–$195,000) in China. The equivalent FDA-approved products in the US list at $373,000–$475,000 for the drug alone, and the full pathway — hospitalization, ICU, supportive care — commonly exceeds $500,000–$1,000,000.
In China, even the total cost of care (product + hospitalization + monitoring) typically runs $157,000–$255,000 — roughly 70–75% below the US full-pathway cost.
Access is another factor. China's NMPA has now approved six commercial CAR-T products (CD19, BCMA, and — since June 2026 — CLDN18.2 for gastric cancer, the world's first CAR-T approved for a solid tumor). It also runs more registered CAR-T clinical trials than any other country. For patients whose cancer doesn't match an approved product, that trial landscape matters.
The hospitals are serious. Leading centers like Ruijin Hospital (Shanghai), Peking University People's Hospital (Beijing) — home of the "Beijing Protocol" for haploidentical transplant — and the national Blood Diseases Hospital (Tianjin) run large, integrated CAR-T and transplant programs with dedicated CAR-T wards and ICU support.
What the decision actually looks like in practice
For an international patient, the process typically starts with a free record review — sending your pathology, imaging, prior treatment lines, and biomarker results to a coordinating team, who confirms whether an approved product fits your case or whether a trial is the better route.
The realistic sequence for many patients:
- Consult your oncologist at home — confirm the diagnosis, prior lines, and whether CAR-T or transplant is indicated
- Get a record review — a Chinese treating team evaluates whether an approved product or trial matches
- Decide the sequence — CAR-T first, transplant to follow, or transplant consolidation
- Plan the stay — 6-10 weeks in China for CAR-T (workup, apheresis, manufacturing, infusion, monitoring)
The most important advice: bring your oncologist into the decision. The best outcomes come from a shared plan between your home team and the Chinese treating team — and good coordinating services translate records both ways.
When the decision is made, the sequence that follows — records, pathology, visa, travel, apheresis — is set out step by step in how to get CAR-T treatment in China.
The honest caveats
First, CAR-T is not a first-line treatment and not a guaranteed cure. Most patients still relapse eventually. The data shows dramatically better response rates than chemo — but "better" is not "cure."
Second, CAR-T and transplant are not always either/or. The strongest evidence points to using them together — CAR-T to reduce disease, transplant to consolidate remission. A single-treatment mindset can miss the better outcome.
Third, CAR-T carries serious risks. Cytokine release syndrome and neurological toxicity are real and can be life-threatening — which is exactly why treatment should happen at a center with dedicated CAR-T wards and ICU support.
Fourth, the real cost is more than the product price. Workup, apheresis, lymphodepletion, inpatient monitoring, and possible ICU care add ¥150,000–¥400,000 in China. Get a written, itemized estimate before committing.
If the patient is a child, read our guide to CAR-T for children with relapsed B-ALL in China first — the paediatric indication, the trial data and the bridge to transplant work differently from the adult pathway.
Getting started with CAR-T in China
If you or a family member is facing this decision, the first step is a free record review. MedChinaGo's CAR-T program works with leading Chinese hematology centers that have dedicated CAR-T wards and ICU support, and provides senior oncology-trained interpreters from record review through Day 30 and Day 90 follow-up. Learn more about CAR-T therapy in China.

